Why Moderna Stock Rallied Today

Shares of Moderna (NASDAQ:MRNA) climbed 7.5% on Tuesday after health officials in the U.K. approved the drugmaker’s COVID-19 vaccine for children ages 12 to 17. 

So what

The Medicines and Healthcare products Regulatory Agency (MHRA) issued a conditional approval for Moderna’s vaccine, now called Spikevax, based on clinical trials that showed the drug to be safe and effective in kids 12 years of age and older. 

Leave a Reply

Your email address will not be published.